Vmn2r30 Inhibitors
Vmn2r30 can employ diverse biochemical mechanisms to modulate the function of this protein. Ledipasvir, while primarily associated with viral protein inhibition, can serve as an archetype for designing molecules that obstruct protein-protein interactions necessary for Vmn2r30 function. Such molecules can bind to Vmn2r30 or its partners and prevent the formation of functional complexes. Palbociclib's selective inhibition of CDKs offers a blueprint for identifying inhibitors that target kinases responsible for the phosphorylation of proteins interacting with Vmn2r30. By blocking these kinases, the phosphorylation-dependent modulation of Vmn2r30-associated proteins can be altered, affecting Vmn2r30's activity.
LY294002 disrupts the PI3K-Akt signaling pathway, which can influence the phosphorylation status of Vmn2r30's intracellular partners, while rapamycin's inhibition of mTOR can similarly lead to reduced activity of proteins that interact with Vmn2r30, thereby modifying its signaling capacity. Maraviroc demonstrates the feasibility of receptor inhibition by stabilizing inactive conformations, a strategy that can be tailored to prevent Vmn2r30 activation. Gefitinib targets the ATP-binding sites of kinases, suggesting that molecules can be designed to inhibit kinases that phosphorylate Vmn2r30 or its associated proteins, thus affecting its function. Allosteric inhibitors such as MLN4924 can alter protein turnover by affecting neddylation, which may stabilize or destabilize Vmn2r30's protein interactors, consequently impacting Vmn2r30's function. DAPT influences the cellular milieu by inhibiting gamma-secretase, leading to the accumulation of substrates that can indirectly affect Vmn2r30's activity. Lastly, U73122 and SB203580 offer insight into how the inhibition of key enzymes like PLC and p38 MAPK can modulate secondary messenger systems and phosphorylation cascades, respectively, which are likely to intersect with the functional pathways involving Vmn2r30.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. While it is primarily used in cancer therapy, the principle of selective inhibition of kinases could be applied to identify chemicals that selectively inhibit the kinases involved in the phosphorylation of proteins that interact with Vmn2r30, thereby inhibiting its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). While it does not target Vmn2r30 directly, it inhibits the PI3K-Akt signaling pathway, which is crucial in many cellular processes. Inhibition of this pathway could decrease the phosphorylation state of intracellular proteins that might interact with Vmn2r30, altering its function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor and while not a direct inhibitor of Vmn2r30, mTOR signaling can regulate the function of a wide variety of proteins through phosphorylation and other post-translational modifications. Inhibition of mTOR could thus suppress the activity of proteins that are necessary for Vmn2r30 signaling, leading to its functional inhibition. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an epidermal growth factor receptor (EGFR) inhibitor. While EGFR and Vmn2r30 are unrelated, the principle of inhibition is through binding to the ATP-binding site of the kinase domain, preventing phosphorylation and activation. Chemicals with similar properties could theoretically inhibit kinases that phosphorylate proteins interacting with Vmn2r30, affecting its activity. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 inhibits neddylation, which affects the activity of cullin-RING ligases (CRLs) involved in protein turnover. By inhibiting neddylation, proteins that are degraded by CRLs and are necessary for Vmn2r30 function might be stabilized, thus potentially inhibiting Vmn2r30 activity by altering its interacting proteins' turnover. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT is a gamma-secretase inhibitor, which prevents the cleavage of various substrates, including Notch. Though not directly affecting Vmn2r30, inhibition of gamma-secretase activity could lead to the accumulation of proteins that could sequester molecules or chaperones necessary for Vmn2r30 function, thereby inhibiting it indirectly. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is an inhibitor of MEK, which is upstream of ERK in the MAPK pathway. By inhibiting MEK, the phosphorylation and thus the activity of ERK is decreased. Since ERK can regulate a plethora of cellular functions including sensory perception, the inhibition of this pathway could reduce the functional activity of Vmn2r30 indirectly. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Inhibiting p38 MAPK can lead to a decrease in the phosphorylation of downstream targets that may be involved in the signaling pathways associated with Vmn2r30, thereby reducing its functional capacity indirectly. | ||||||